Novo Nordisk A/S Sees Unusually High Options Volume (NYSE:NVO)

Key Points

• Traders purchased a significant volume of 65,836 call options for Novo Nordisk A/S, reflecting a 31% increase from the average volume.
• Institutional investments have surged, with Kingstone Capital Partners increasing its holdings by over 300,000% and several institutions acquiring positions worth hundreds of millions.
• Analyst ratings on Novo Nordisk A/S are mixed, with HSBC downgrading the stock while Wall Street Zen upgraded it from "hold" to "buy," highlighting the varying outlooks among analysts.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) was the recipient of unusually large options trading activity on Friday. Traders purchased 65,836 call options on the stock. Thisrepresentsanincreaseofapproximately31% compared to the average volume of 50,247 call options.

Analysts Set New Price Targets

Several equities analysts have weighed in on NVO shares. Wall Street Zen cut shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research report on Saturday. Barclays reiterated an "equal weight" rating on shares of Novo Nordisk A/S in a research report on Wednesday, July 30th. Guggenheim cut shares of Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a research report on Thursday, April 17th. BMO Capital Markets reiterated a "market perform" rating and set a $64.00 price objective (down from $105.00) on shares of Novo Nordisk A/S in a research report on Thursday, April 17th. Finally, Hsbc Global Res cut shares of Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a research report on Thursday. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average price target of $93.67.

Novo Nordisk A/S Stock Up 1.4%

Shares of NVO stock traded up $0.68 on Monday, hitting $48.87. The company's stock had a trading volume of 6,572,592 shares, compared to its average volume of 10,692,935. The company has a debt-to-equity ratio of 0.70, a current ratio of 0.74 and a quick ratio of 0.56. Novo Nordisk A/S has a fifty-two week low of $46.90 and a fifty-two week high of $139.74. The firm's fifty day moving average price is $69.26 and its 200-day moving average price is $72.58. The stock has a market capitalization of $218.20 billion, a price-to-earnings ratio of 14.46, a P/E/G ratio of 1.46 and a beta of 0.63.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The company reported $0.92 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.92. The business had revenue of $11.87 billion during the quarter. Novo Nordisk A/S had a net margin of 34.52% and a return on equity of 80.94%. Research analysts anticipate that Novo Nordisk A/S will post 3.84 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Strategic Investment Solutions Inc. IL lifted its position in Novo Nordisk A/S by 2,727.3% during the 4th quarter. Strategic Investment Solutions Inc. IL now owns 311 shares of the company's stock worth $27,000 after acquiring an additional 300 shares during the last quarter. Copeland Capital Management LLC lifted its position in Novo Nordisk A/S by 184.8% during the 1st quarter. Copeland Capital Management LLC now owns 393 shares of the company's stock worth $27,000 after acquiring an additional 255 shares during the last quarter. North Capital Inc. acquired a new position in Novo Nordisk A/S during the 1st quarter worth $27,000. Park Square Financial Group LLC acquired a new position in Novo Nordisk A/S during the 4th quarter worth $29,000. Finally, Stone House Investment Management LLC acquired a new position in Novo Nordisk A/S during the 1st quarter worth $30,000. Institutional investors and hedge funds own 11.54% of the company's stock.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.